Topical psoriasis therapy: An innovative classic

Introduction. Psoriasis affects various aspects of the quality of life of patients, causing psycho-emotional stress, anxiety and depression, therefore treatment of patients in terms of long-term control is the main goal of therapy.

Aim. To study the effectiveness of drugs containing calcipotriol and betamethasone in the treatment of plaque psoriasis of smooth skin, scalp, palmoplantar mild to moderate severity.

Material and methods. We observed 59 patients and 32 patients with moderate plaque psoriasis (PASI > 10 and < 20 points). In the groups, patients were randomized into subgroups with mild and moderate severity of psoriasis.

Results. In patients with mild and moderate plaque psoriasis, after 4 weeks there was a decrease in the PASI index by 89.1% and 64.1%, respectively, the DLQI index decreased by 53.8% and 61.9%, the sPGA index by 71.8% and 64.9% for mild and moderate degrees, respectively. In patients with mild and moderate palmoplantar psoriasis, after 4 weeks there was a decrease in the PPASI index by 64.2% and 62.1%, respectively, the DLQI index decreased by 56.4% and 56.7%, and the sPGA index by 63.4 % and 66.7% for mild and moderate degrees, respectively. In patients with mild to moderate psoriasis of the scalp, after 4 weeks there was a decrease in the PSSI index by 75.1% and 72.6%, the DLQI index decreased by 64.6% and 69.6%, and the sPGA index by 62.3% and 67.6% for mild and moderate degrees, respectively.

Conclusion. A 52-week follow-up demonstrated the effectiveness and safety of therapy with combination drugs (Daivobet® and Xamiol®) in patients with plaque psoriasis, including scalp psoriasis and palmoplantar psoriasis. It also showed a pronounced positive effect on the quality of life of patients, including in terms of long-term control of the disease.

1. Круглова ЛС, Бакулев АЛ, Коротаева ТВ, Лила АМ, Переверзева НО. Псориаз. М.: ГЭОТАР-Медиа; 2022. 328 с.

2. Кубанов АА, Карамова АЭ, Притуло ОА, Аршинский МИ, Знаменская ЛФ, Чикин ВВ и др. Псориаз: клинические рекомендации. М.; 2023. 78 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/234_2.

3. Kruglova LS, Samushiia MA, Talybova AM. Mental disorders, social maladaptation and quality of life of patients with acne and post-acne symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12):4–10. (In Russ.) https://doi.org/10.17116/jnevro20181181214.

4. Samushiya MA, Rozhkova YuI, Vinogradov DL, Kruglova LS, Lobanova VM, Zateyshchikov DA. Somatoreactive cyclotymia. somatic diseases competing for the role of rhythm oscillator of affective pathology: psoriasis and pulmonary arterial hypertension. Kremlin Medicine Journal. 2021;4:102–108. (In Russ.) Available at: https://kremlin-medicine.ru/index.php/km/article/view/1527.

5. Vladimirova IS, Kruglova LS. Efficacy of therapy with the interleukin-23 inhibitor а guselkumab and quality of life indicators in patients with psoriasis. Effective Pharmacotherapy. 2024;20(1):18–26. (In Russ.) https://doi.org/10.33978/2307-3586-2024-20-1-18-26.

6. Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun. 2015;64:66–73. https://doi.org/10.1016/j.jaut.2015.07.008.

7. Kruglova LS, Moiseev SV. Inhibition of interkeukin-17 – new horizons of efficacy and safety in the treatment of psoriasis. Clinical Pharmacology and Therapy. 2017;26(2):5–12. (In Russ.) Available at: https://clinpharm-journal.ru/articles/2017-2/blokada-interlejkina-17-novye-gorizonty-effektivnosti-ibezopasnosti-v-lechenii-psoriaza/.

8. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2012;304(2):87–113. https://doi.org/10.1007/s00403-012-1214-8.

9. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–659. https://doi.org/10.1016/j.jaad.2008.12.032.

10. Bartosik-Psujek H, Tabarkiewicz J, Pocinska K, Stelmasiak Z, Rolinski J. Immunomodulatory effects of vitamin D on monocyte-derived dendritic cells in multiple sclerosis. Mult Scler. 2010;16(12):1513–1516. https://doi.org/10.1177/1352458510379611.

11. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008;324(1):23–33. https://doi.org/10.1124/jpet.107.127209.

12. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O’Garra A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol. 2001;167(9):4974–4980. https://doi.org/10.4049/jimmunol.167.9.4974.

13. Colin EM, Asmawidjaja PS, van Hamburg JP, Mus AM, van Driel M, Hazes JM et al. 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum. 2010;62(1):132–142. https://doi.org/10.1002/art.25043.

14. Peric M, Koglin S, Dombrowski Y, Gross K, Bradac E, Büchau A et al. Vitamin D analogs differentially control antimicrobial peptide/“alarmin” expression in psoriasis. PLoS ONE. 2009;4(7):e6340. https://doi.org/10.1371/journal.pone.0006340.

15. Hegyi Z, Zwicker S, Bureik D, Peric M, Koglin S, Batycka-Baran A et al. Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 “alarmins” psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. J Invest Dermatol. 2012;132(5):1416–1424. https://doi.org/10.1038/jid.2011.486.

16. Lovato P, Norsgaard H, Tokura Y, Røpke MA. Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis. J Dermatol Sci. 2016;81(3):153–164. https://doi.org/10.1016/j.jdermsci.2015.12.009.

17. Skripkin YuK, Bogush PG, Kruglova LS, Dvornikov AS. New possibilities for the external therapy of psoriasis. Vestnik Dermatologii i Venerologii. 2006;(3):33–36. (In Russ.) Available at: https://elibrary.ru/isduov.

18. Kruglova LS. The use of external agent “Davonex” in combination with phototherapy in the treatment of psoriasis. RMJ. 2002;10(4):216–217. (In Russ.) Available at: https://www.rmj.ru/articles/dermatologiya/Primenenie_narughnogo_sredstva_Dayvoneks_v_sochetanii_s_fototerapiey_pri_lechenii_psoriaza/.

19. Kruglova LS, Dvornikov SK. Daivobet – long-term control of psoriasis. Consilium Medicum. Dermatology (Suppl.). 2010;(3):22–26. (In Russ.) Available at: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consiliummedicum/cm2010/derma2010_pril/derma2010_3_pril/dayvobetdolgosrochnyy-kontrol-nad-psoriazom/.

20. Kruglova LS, Zhukova OV. Psoriasis of the scalp: modern methods of treatment and the possibility of long-term control of the disease. Russian Journal of Clinical Dermatology and Venereology. 2014;12(1):86–93. (In Russ.) Available at: https://www.mediasphera.ru/issues/klinicheskaya-dermatologiyai-venerologiya/2014/1/031997-28492014115.

21. Kruglova LS, Mordovtseva VV, Zhukova OV, Serov DN. Combination of calcipotriol and betamethasone in psoriasis treatment. Russian Journal of Clinical Dermatology and Venereology. 2014;12(6):54–63. (In Russ.) Available at: https://www.mediasphera.ru/issues/klinicheskayadermatologiya-i-venerologiya/2014/6/031997-2849201469.

22. Kruglova LS, Lvov AN, Ismailov AA, Marochkina EE, Tomilov EV, Petrunin DD. Results of an observational study in patients with psoriasis vulgaris who received long-term topical therapy (PSO-CONTROL). Russian Journal of Clinical Dermatology and Venereology. 2022;21(5):610–618. (In Russ.) https://doi.org/10.17116/klinderma202221051610.

23. Kruglova LS, Turbovskaya SN, Khotko AA. Scalp psoriasis – topical issues of diagnosis and therapy. Farmateka. 2018;(S5):35–42. (In Russ.) https://doi.org/10.18565/pharmateca.2018.s5.35-42.

24. Jacobson CC, Kimball AB. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol. 2004;151(2):381–387. https://doi.org/10.1111/j.1365-2133.2004.06035.x.

25. Kornisheva VG, Smolina OA, Stepanova AA, Avdeenko YuL, Raznatovsky KI. Clinical and morphological features of psoriasis of the scalp depending on contamination by fungi of the genus Malassezia. Russian Journal of Clinical Dermatology and Venereology. 2020;19(3):366–372. (In Russ.) https://doi.org/10.17116/klinderma202019031366.

26. Karamova AE, Olisova OYu, Bakulev AL, Kokhan MM, Khairutdinov VR, Sokolovskiy EV, Khobeych MM. Revisiting the question of psoriasis classification. Vestnik Dermatologii i Venerologii. 2021;97(5):18–25. (In Russ.) https://doi.org/10.25208/vdv1267.

27. Cappelleri JC, Bushmakin AG, Harness J, Mamolo C. Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity. Qual Life Res. 2013;22(9):2489–2499. https://doi.org/10.1007/s11136-013-0384-y.

28. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. https://doi.org/10.1111/j.1365-2230.1994.tb01167.x.